| Primary Biliary Cholangitis
Livdelzi vs Iqirvo
Side-by-side clinical, coverage, and cost comparison for primary biliary cholangitis.Deep comparison between: Livdelzi vs Iqirvo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsIqirvo has a higher rate of injection site reactions vs Livdelzi based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Iqirvo but not Livdelzi, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Livdelzi
Iqirvo
At A Glance
Oral
Daily
PPAR-delta agonist
Oral
Daily
PPAR agonist
Indications
- Primary Biliary Cholangitis
- Primary Biliary Cholangitis
Dosing
Primary Biliary Cholangitis 10 mg orally once daily, with or without food; when taking bile acid sequestrants, administer at least 4 hours before or after.
Primary Biliary Cholangitis 80 mg orally once daily with or without food; administer at least 4 hours before or 4 hours after a bile acid sequestrant.
Contraindications
—
—
Adverse Reactions
Most common (>=5%) Headache, abdominal pain, nausea, abdominal distension, dizziness
Serious Fractures, liver test abnormalities
Most common (>=5%) Weight gain, diarrhea, abdominal pain, nausea, vomiting, arthralgia, constipation, muscle pain, fracture, gastroesophageal reflux disease, dry mouth, weight loss, rash
Serious Myalgia, myopathy, rhabdomyolysis, fractures, drug-induced liver injury, hypersensitivity reactions
Pharmacology
Seladelpar is a PPAR-delta agonist that activates PPAR-delta, a nuclear receptor expressed in most tissues including the liver, inhibiting bile acid synthesis via FGF21-dependent downregulation of CYP7A1, the key enzyme for bile acid synthesis from cholesterol; the exact mechanism of therapeutic benefit in PBC is not fully understood.
Elafibranor and its active metabolite GFT1007 are PPAR agonists that activate PPAR-alpha, PPAR-gamma, and PPAR-delta in vitro, with pharmacological activity potentially relevant to PBC including inhibition of bile acid synthesis through PPAR-alpha and PPAR-delta activation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Livdelzi
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
Iqirvo
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Livdelzi
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (5/8)
Iqirvo
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (5/8)
Humana
Livdelzi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Iqirvo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Primary Biliary Cholangitis
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Primary Biliary Cholangitis
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
LivdelziView full Livdelzi profile
IqirvoView full Iqirvo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.